Health Boards
Tue-01-04-2014, 11:34 AM
Following on from the European Commission, USA, Canada, and Scotland. England have decided Stelara will not be used for psoriatic arthritis. It works and I'm living proof of that, Boo Hiss to you England. 
Come on England the rest agree it works, and what about people like me where nothing else worked.
[To see links please register here]
Quote:
Final draft guidance, from the National Institute for Health and Care Excellence, published today does not recommend ustekinumab (Stelara) for psoriatic arthritis.
Ustekinumab (Stelara) is not recommended within its marketing authorisation for treating active psoriatic arthritis, that is, alone or in combination with methotrexate in adults when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.
People currently receiving treatment initiated within the NHS with ustekinumab that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
The Committee concluded that ustekinumab is not a cost-effective treatment option for people who have not previously received TNF alpha inhibitors, for those cannot take them, or for those who have received TNF alpha inhibitors. In the economic analysis for people who have not previously received TNF alpha inhibitors (the ‘TNF alpha inhibitor-naive' population), ustekinumab was dominated by - that is, was more expensive and less effective than - adalimumab. In all other populations, including people who have previously received TNF alpha inhibitors (the ‘TNF alpha inhibitor-exposed' population) and people for whom TNF alpha inhibitors are not appropriate, the most plausible incremental cost-effectiveness ratio (ICER) for ustekinumab is likely to exceed £30,000 per quality-adjusted life year (QALY) gained.
Come on England the rest agree it works, and what about people like me where nothing else worked.